A trial fibrillation (AF) is a disease of disordered electric conduction of the cardiac atria and is the most common cardiac arrhythmia. 1 It affects 33 million people worldwide and 6 million in the United States-a number expected to double by 2030. 2 AF contributes significantly to morbidity, mortality, and healthcare costs with annual healthcare expenditures of $33 billion in 2013. 3, 4 AF caused 130 000 deaths in 2013. 2 Patients with AF are 2 to 10× more likely to have embolic strokes originating from the fibrillating atria. 2 The pathophysiology of AF is complex and difficult to treat. Heart disease and systemic diseases lead to foci of overexcitable atrial cardiomyocytes and shortening of atrial cardiomyocyte action potential duration propagation of rapid conduction. 5 Together, these changes foster multiple random propagating wavelets, focal electric discharges, and localized reentrant activity that prevent coordinated atrial contraction. 6 There are several medications to control atrial rhythm in patients with AF, but none have shown a mortality benefit, due in part to the poor success at achieving normal sinus rhythm (NSR). [7] [8] [9] Clinical trials have also shown improved quality of life with restoration of NSR when achievable. 10, 11 Some rhythm control medications increase risk of arrhythmia, heart failure, or death and are contraindicated in many patients with cardiac disease (ironically, the largest population with AF). 1 Because of the low success rates and toxicity, only 16% of patients with AF are treated with rhythm control strategy. 12 Invasive procedures, such as AF ablation, are available for patients with symptoms refractory to medical treatment, but the outcomes are poor for more advanced disease stages (persistent AF). 13 Amiodarone is a lipophilic medication approved in the United States for the treatment of ventricular arrhythmias and used off-label for the treatment of AF.
14 Amiodarone prolongs atrial refractoriness and action potential duration, reducing early excitation in both normal and diseased hearts. 15 In a recent Cochrane analysis, amiodarone had the lowest number needed to treat, 3, to prevent recurrence of AF and significantly reduced the recurrence compared with dronedarone and sotalol. 8 Amiodarone is an effective medication, but its use is associated with significant off-target tissue toxicity. Off-target tissue levels are estimated to be 10 to 500× higher than cardiac levels in patients taking chronic amiodarone. 16, 17 Risk of pulmonary fibrosis, thyroid toxicity, and liver dysfunction ranges from 18% to 75% of patients taking chronic amiodarone. 16, 18 Thus, amiodarone is recommended only as an agent of last resort by American, European, and Canadian guidelines. 19 Recently, we described a catheter-based technique using a novel device to deliver hydrogels to the cardiac epicardium under fluoroscopic guidance. 20 This delivery technique creates a temporary compartment on the
WHAT IS KNOWN?
• Atrial fibrillation is the most common cardiac arrhythmia.
• Rhythm control may reduce morbidity and hospitalization but is difficult to attain in many patients.
• Amiodarone is an effective rhythm control medication but has significant systemic toxicity.
WHAT THE STUDY ADDS?
• Amiodarone can be delivered directly to the heart encapsulated in hydrogel.
• With this method, 50 mg of amiodarone reduces atrial fibrillation for 1 month.
• Minimally invasive epicardial delivery of hydrogels is a translatable method to deliver therapeutics to the heart. heart's surface for hydrogel delivery and in situ polymerization allowing precise localization and gelation. This technique could be used to deliver hydrogels with various therapeutic materials and mechanisms of action. Hydrogels are under investigation for various cardiac applications but few specialized delivery methods have been designed. [21] [22] [23] [24] [25] Intracoronary administration of hydrogels could lead to thrombosis or myocardial infarction. Intramyocardial injection by left ventricular catheter, such as Noga Myostar injection catheter, could also cause embolic events. Intramyocardial injection at the time of cardiac surgery would limit eligible patients.
Here, we explore the efficacy of an amiodaronecontaining hydrogel delivered to the epicardium of the cardiac atria in a large-animal model of AF. Amiodarone delivered in this way could have multiple advantages over systemic dosing, the most important of which is localized drug delivery to the affected cardiac muscle and lessened off-target organ toxicity. This technology represents a new strategy for the treatment of AF, utilizing an existing effective medication that was formally limited by off-target organ toxicity. More broadly, this strategy could facilitate delivery of new cardiac therapeutics to the heart, including stem cells, microRNAs, viral based therapies, exosomes and protein in a precise and effective manner.
MATERIALS AND METHODS
Details of the data, analytic methods, and study materials not provided in this text will be been made available to other researchers on request for purposes of reproducing the results or replicating the procedure.
Gel Synthesis and In Vitro Analysis
Polyethylene glycol (PEG) hydrogels based on a 4-arm PEG macromer (20 kDa; Laysan Bio, Arab, AL) with maleimides at each terminus (PEG-4MAL) were crosslinked with dithiothreitol and the bicysteine peptide VPM (GCRDVPMSMRGGDRCG). This platform provides structurally defined hydrogels with stoichiometric incorporation of ligands that has been extensively studied for biological applications. 20, 23, 26, 27 Hydrogel components were adjusted to yield a 5-mL gel of a 4.0% wt/vol PEG hydrogel containing 50 mg of polysorbate-solubilized amiodarone.
For the release study, amiodarone hydrochloride (SigmaAldrich) was loaded into 20-µL hydrogels after solubilization in polysorbate 80. For solubilization, polysorbate 80 solutions (ratios of polysorbate 80:saline: 5:95, 10:90, 20:80, and 30:70 v/v) were added to amiodarone to a final concentration of 50 mg/mL. This solution was then heated to 60°C and vortexed vigorously for 1 minute. This amiodarone solution was then added to the hydrogel components and the hydrogel cross-linked with dithiothreitol and VPM (1:1). After gelation, hydrogels were incubated in 500 µL of 10% human serum in PBS. At specified time points, all 500 µL was removed and replaced with fresh 500 µL of 10% human serum in PBS. Supernatants were frozen at −80° C and stored until analysis by high-purity liquid chromatography as has been described previously. 28 Samples were separated on a Kinetex 5 µm C18 column (150×4.6 mm). The mobile phase, consisting of phosphate buffer (50 mmol/L) with 0.5% formic acid (pH 4.5)-methanol-acetonitrile (45:5:50, v/v/v), was pumped isocratically at a flow rate of 1.0 mL/min. The detection was conducted at 254 nm.
Pericardial Hydrogel Delivery in Rats
A rodent model of pericardial drug delivery was used to study amiodarone accumulation to target and off-target tissues. All rodent studies were approved by the Emory University Animal Use and Care Committee and performed in accordance with National Institutes of Health guidelines. Male Sprague-Dawley rats (200-250 g; Charles River, Wilmington, MA) were anesthetized with isoflurane and intubated. A thoracotomy was performed from the anterior approach, exposing the left lung and heart. The lung was gently retracted with sterile gauze and the pericardium grasped with burr-free atraumatic forceps. A blunted 26 G, 0.5-inch needle with # 5 style blunt tip was attached to a 100-μL syringe (Hamilton Company, Reno, NV) and was used to gently penetrate the tended pericardium. A 100-μL hydrogel containing 1 mg amiodarone (n=6) was delivered into the pericardial space and gelation confirmed by visualization of gel surrounding the heart confined by the pericardial sac. After 1 month, animals were euthanized and heart, lung, thyroid, liver, fat, and gel remnants collected for tissue amiodarone measurements by high-purity liquid chromatography. Additional rats (n=6) were treated with systemic amiodarone via daily intraperitoneal injection (10 mg/kg) for 28 days resulting in a cumulative dose of ≈100 mg for 1 month depending on animal size and growth rate. 
Large-Animal AF Model
The objective of this study was to create a large-animal AF model that did not disrupt the pericardial space. 30 All pigs received antibiotics by intramuscular daily injection (cephalexin, 5 mg/kg) to prevent hardware infection for the duration of the experiment and colchicine by mouth twice daily (0.6 mg) to prevent pericardial inflammation. Male farm pigs of 50 to 55 kg were used to simulate heart and pericardial size to adult humans. Seven days before gel implantation, animals were sedated and the right neck and internal jugular vein exposed. A chronic resynchronization therapy pacemaker (CRT-P) was implanted (Viva; Medtronic, Minneapolis, MN). The CRT-P is designed to clinically deliver 3 leads of output for the purpose of optimizing atrial and ventricular synchrony in heart failure. 31 Unlike the clinical configuration with a single lead in the atrium, we positioned all 3 leads (CapSureFix; Medtronic) in the right atria with one in the right atrial appendage, high free wall, and low free wall. Tined, bipolar permanent pacing leads were introduced, advanced under fluoroscopic guidance. Each position was tested for capture threshold <2 V and sensing electrogram >2 mV. Lack of diaphragmatic stimulation at maximal output was also confirmed. Leads were connected to the CRT-P and programmed to rapidly pace in a dual atrial and ventricular mode, DOO (150 beats per minute pacing, with 140 ms atrioventricular delay and then 80 ms right-to-left ventricular lead delay), using clinical programer parameters. Maximal output, 8 V, was used. The left neck and jugular vein were also used to implant a single-chamber pacemaker (Advisa; Medtronic) with lead terminating in the right ventricular apex and set in a ventricularly paced mode, VOO, at a rate of 100. Lastly, animals underwent His bundle ablation after receiving bolus of lidocaine (75 mg, IV). A Blazer II (Boston Scientific) radiofrequency ablation catheter was advanced from the femoral vein to the atrioventricular node and positioned to optimize the His Bundle signal on intracardiac electrogram. Sixty watts of power at 60°C for ≤30 seconds was used for each ablation. Pigs required between 1 and 4 ablations to achieve heart block. Ventricular arrhythmias generated by ablation were immediately cardioverted with external defibrillation.
Hydrogel implantation was performed 7 days after pacemaker implantation. Animals were placed recumbent on cardiac catheterization suite table (Allura FDA 10: Xper; Philips) and subxiphoid sterilely prepped and draped. A micropuncture needle was used to access the pericardial space under fluoroscopic guidance as has been described and used with other pericardial devices. 32 Our hydrogel-delivery device was placed over the atrial epicardium (posterior, inferior) using a posteriorly directed sheath. The delivery device was advanced outside of the sheath and formed a temporary compartment for hydrogel delivery as has been recently described. 20 Negative pressure suction held the device in a stable position on the beating epicardium and temporarily sealed the hydrogel compartment. Hydrogel components were kept separated in 2 lumens and delivered to the atrial epicardium. The delivery device and suction was held in place for 5 minutes to allow for gelation. The suction was slowly released and device unwound from around the gel without disruption of gel architecture. During gel-delivery procedure, animals were invasively monitored for hemodynamic changes with a Swan-Ganz catheter and arterial pressure line.
Electrophysiological Testing
At weekly intervals, animals were sedated and electrophysiological study performed using the CRT-P. After cessation of overdrive atrial pacing, atrial rhythm was monitored for 30 minutes via intracardiac electrograms and 12 lead EKG. The timing of spontaneous cardioversion into NSR was recorded. If animals did not cardiovert spontaneously, NSR was achieved by synchronized external defibrillation at 180 J to allow for subsequent testing. At least 5 minutes elapsed before further testing to allow for normalization of electrophysiological conduction. Inducibility of AF was tested by performing atrial pacing at 50 Hz for 10 seconds using the CRT-P right atrial appendage lead. Ten trials were performed for each animal at each time point and the number of inductions of AF lasting >1 minute was recorded weekly.
Tissue Processing and Amiodarone Quantification
Fresh or frozen tissue was diced into 5-mm 2 sections and further homogenized using automated TissueLyzer (Qiagen, Germantown, MD). Amiodarone was extracted using acetonitrile, n-hexane, and methanol and analyzed by high-purity liquid chromatography as was done for in vitro experiments. 28 Tissue for histological evaluation was fixed in formalin, dehydrated using a graded series of ethyl alcohols and xylene, paraffin embedded, and stained with Masson trichrome. Five-micrometer-thick sections were imaged using automated slide scanner and representative ×10 magnification sections (NanoZoomer; Hamamatsu, Bridgewater, NJ). Histological sections were evaluated by board-certified pathologist blinded to the treatment groups. Colormetric segmentation was performed using ImageJ using the threshold function to maximize detection with lower limit of 120 and upper limit set to 190. Measurement of thresholded area was calculated as a percentage of the total area of each ×10 image. For each animal, 3 distinct areas of the left atria were measured and averaged. Blood was collected from peripheral vein for serum markers performed using VetScan chemistry analyzer (Abaxis, Union City, CA) and white blood cell counts using automated hemocytometer.
Statistical Analysis
Data are expressed as mean±SEM. Statistical calculations were performed using GraphPad Prism 6 (GraphPad Software, Inc) as indicated in the test. Differences between group means were compared using unpaired Student t test with correction for repeated measures by the Holm-Sidak method where appropriate. Multiple groups were compared using ANOVA with Tukey multiple comparison test.
RESULTS

Amiodarone Encapsulation in a Synthetic Hydrogel Achieves Extended Drug Release In Vitro
Amiodarone was encapsulated in a PEG-based hydrogel-a gel platform that has shown significant advantages, such as cytocompatability and controlled polymerization, tunable biophysical and biochemical properties, and minimal inflammation and toxicity. 23, 26, 27 Gel components were also selected because of their use in other clinically approved drugs and devices. The hydrogel was synthesized using a 4-arm PEG-maleimide macromer (Laysan Bio, Arab, AL) cross-linked via the terminal maleimides and dithiolpresenting molecules. Amiodarone was solubilized in different concentrations of polysorbate 80 before loading into the gel. Gels were kept under simulated physiological temperature and motion. Release kinetics showed an initial release bolus of <20% for amiodarone solubilized with either 5% or 10% polysorbate 80 and 30% and 52% release for amiodarone solubilized with 20% and 30% polysorbate 80, respectively ( Figure 1 ). Forty-eight hours after encapsulation, gels having amiodarone solubilized in 5% or 10% polysorbate 80 retained >40% of the initial dose. All subsequent experiments were conducted using amiodarone (50 mg/mL) solubilized in 10% polysorbate 80 and encapsulated in PEG hydrogel.
Epicardial Delivery of AmiodaroneContaining Gel Reduces Off-Target Drug Accumulation
To test amiodarone tissue distribution, a 100-μL gel containing 1 mg of amiodarone was delivered into the pericardial space of rats via thoracotomy and compared with animals receiving daily systemic (intraperitoneal) amiodarone at a clinically equivalent dose (10 mg/kg per day). After 28 days, animals treated with systemic amiodarone (Figure 2A , black bars) had higher accumulation of drug in off-target organs compared with epicardial amiodarone-containing gel-treated animals including the fat (36.1±10.7 versus 1.3±0.2 μg/g; P=0.02), lung (7.1±1.4 versus 0.9±0.1 μg/g; P=0.001), thyroid (86.7±20.8 versus 1.9±0.3 μg/g; P=0.002), and liver (2.8±0.9 versus 0.7±0.1 μg/g; P=0.03). Drug levels in the thyroid, lung, and liver were 45×, 8×, and 3× higher, respectively, in systemically dosed animals compared with gel-dosed animals.
Cardiac amiodarone levels were low in both groups but higher in systemically dosed rats compared with gel-treated rats at days 7 (5.4±5.1 versus 0.2±0.03 µg/g; P=0.04) and 28 (2.7±0.4 versus 1.1±0.1 μg/g; P=0.004; Figure 2B ). However, a higher proportion of the total administered dose was present in the heart of gel-treated animals after 28 days (0.09±0.001% versus 0.001±0.0003%; P<0.001). Cardiac drug levels in amiodarone gel-treated animals increased from day 7 to 28 suggesting continual drug release over time (0.2±0.03 versus 1.1±0.3 μg/g; P=0.01; Figure 2B, black bars) . Recovered portions of the amio- Figure 1 . Amiodarone encapsulation extends drug release. Hydrogels were synthesized with amiodarone solubilized at differing concentrations of polysorbate 80 in saline after which amiodarone release was analyzed over time via high-purity liquid chromatography. After 3 d in simulated in vivo conditions (37°C, 1 Hz shaking), hydrogels containing amiodarone solubilized with 5% or 10% polysorbate 80 retained >30% of total loaded amiodarone, whereas hydrogels containing amiodarone solubilized with 20% or 30% polysorbate exhibited almost complete amiodarone release. n=2 to 3, error bars±SEM. 
Hydrogel Was Delivered to the Atrial Epicardium Using a Minimally Invasive Procedure
Using a micropuncture needle to access the pericardial space percutaneously, a hydrogel-delivery device was positioned over the atrial epicardium in all 9 animals ( Figure 3) . Gel was delivered to the desired location with procedure times from skin puncture to sheath removal lasting 26.1±10.8 minutes (n=9). Four animals were treated with a 5-mL hydrogel containing amiodarone (50 mg) and 4 with control gel of the same size containing no drug. One additional animal was excluded before gel implantation because of infection not related to gel. This amiodarone dose was the maximal quantity that could be incorporated into the gel without significant precipitation. Invasive hemodynamic parameters measured during the implantation procedure did not change acutely or after 4 weeks ( Table 1) .
Atrial Overdrive Pacing Using CRT-P Promotes AF
Overdrive pacing of the cardiac atria in pigs is an established large-animal model of AF. 30, 33 Instead of utilizing a neurostimulator generator to achieve cycle lengths of 10 Hz at a single location in the atria, we implanted 3 leads attached to a CRT-P in the right atria to more closely model the electric disorganization of AF (Figure 4) . One animal was excluded because of development of pacemaker pocket wound dehiscence and infection 7 days after implantation of CRT-P. Three animals had a pacemaker lead dislodgement detected by CRT-P interrogation and underwent successful lead revision the week before gel placement. One week after atrial overdrive pacing, control animals sustained AF for 0.75±1.5 minutes after temporary cessation of overdrive pacing (Figure 5A) . After 14 days, AF was sustained for 9.75±13.5 minutes, which is similar in scope to AF achieved by neurostimulator pacing in published studies. 
Epicardial Amiodarone-Containing Gel Reduces AF
Nine pigs underwent implantation of the CRT-P device in the right neck and 3 pacing leads (Medtronic) implanted in the right atrium via the internal jugular vein. In all animals, leads were distributed in the right atria in 3 distinct locations: right atrial appendage, upper lateral wall, and lower lateral wall. This configuration achieved sensing and pacing threshold goals but avoided diaphragmatic stimulation. Six of 9 animals required external defibrillation during His ablation from ventricular tachycardia or ventricular fibrillation, and all were successfully cardioverted.
At weekly intervals, animals underwent electrophysiological study. After 2 weeks of overdrive pacing, animals in the control group sustained AF and by 3 weeks, tended to remain in AF for the full 30 minutes after cessation of overdrive pacing. In contrast, animals treated with amiodarone-containing hydrogel spontaneously cardioverted into NSR during the monitoring period, and not a single animal maintained AF for the 30 minutes in the treatment group ( Figure 5B Figure 5B ). While awake, animals have higher heart rates and levels of adrenergic stimulation that could influence their propensity for AF. We confirmed that amiodarone-containing hydrogel significantly reduced the duration of sustained AF in awake animals at 19 (23.3±13.5 versus 0.75±1.5 minutes; n=4; P<0.05) and 26 days (25.5±9.0 versus 2.3±2.9 minutes; n=4; P<0.05) after hydrogel delivery. Statistical significance was calculated using Student t test corrected for multiple comparisons using the Holm-Sidak method (α=5.000%).
The inducibility of AF was also investigated using 10-second 50 Hz burst stimulation-a maneuver known to trigger AF. Animals treated with amiodarone-containing gel had fewer AF inductions in response to 50 Hz stimulation 14 (8.0±4.0 versus 2.5±4.4 attempts; P=0.039) and 21 (9.7±0.6 versus 2.5±3.1 attempts; P=0.013) days after gel delivery ( Figure 5C ). At 28 days, the positive inductions were lower in amiodarone hydrogel-treated animals but failed to meet statistical significance (7.5±1.9 versus 3.5±4.1; n=4; NS) because of lack of inducibility in 1 control animal at this time point. Cardiac amiodarone levels in pigs were the highest in the left atrium (0.11±0.05 µg/g) and pericardial fat (0.14±0.08 µg/g). Taken together, these results show that a 1-time treatment with amiodarone-containing hydrogel is capable of reducing the duration of sustained AF and the propensity for induction of AF for at least 1 month in a large-animal model of chronic overdrive atrial pacing.
Amiodarone-Containing Gel Was Nontoxic to the Heart, Liver, and Lungs
Atrial fibrosis has been linked to progression of AF in patients and animal models. 33, 34 Treatments that reduce AF, including amiodarone, have been reported to reduce atrial fibrosis in animal models. 33 Inflammation, if triggered by gel, could also cause atrial fibrosis. Tissue sections from the left atria were fixed and stained with Masson trichrome and fibrosis measured by nonbiased colormetric analysis with Image J. There was no difference between control hearts from animals without any cardiac manipulation (NSR) and AF animals. Furthermore, amiodarone content of gel did not increase detectable fibrosis (24.1±6.6% versus 26.2±7.3%; n=4; NS; Figure 6A ) using Tukey multiple comparison test.
To rule out the possibility of pulmonary toxicity in animals treated with amiodarone-containing gel, tissue sections from the posterior basal inferior lobe of the lung were collected and evaluated by 2 board-certified pathologists blinded to treatment condition. This location was chosen because of its close anatomic position to the location of gel delivery. In all 4 control gel-treated animals and 2 amiodarone-containing gel animals, mild focal inflammation was reported, including patchy bronchiolitis and mild interstitial pneumonitis-like inflammation. Overall, no significant lung inflammatory findings were preset in either group. Serum markers of liver function (albumin, alkaline phosphatase, ALT [alanine aminotransferase], and bilirubin) showed no significant change during the course of the experiment ( Figure 6B ; Table 2 ). Creatinine as a marker of kidney function was higher at baseline in the amiodarone-con- taining gel-treated group but remained stable during the course of the experiment (Table 2) .
DISCUSSION
Here, we describe a new and effective strategy to treat AF by delivering hydrogel-encapsulated amiodarone directly to the heart through the pericardial space. Pigs treated with a single dose of amiodarone-containing hydrogel (50 mg amiodarone/5 mL gel) delivered to the atrial epicardium had reduced duration and inducibility of AF for at least 4 weeks compared with empty gel controls ( Figure 5 ). The gel was successfully delivered in a minimally invasive procedure. Using a rat model to study drug tissue distribution, systemically administrated amiodarone resulted in significant drug accumulation in off-target organs ( Figure 2A ) consistent with other studies. 16, 17, 35 In contrast, epicardial gel-treated animals had significantly lower off-target organ drug accumulation, drastically so in the case of the fat, liver, and thyroid. Recovered portions of epicardial amiodarone gel still contained drug at 7 and 28 days postdelivery (Figure 2A ). Continued drug availability in the gel is evidenced by increasing cardiac drug levels in this group from days 7 to 28. These data show proof of principle that epicardial hydrogels can (1) deliver therapeutics directly to the heart, (2) achieve continued release for several weeks, and (3) reduce off-target organ accumulation. Thus, epicardial hydrogel delivery may be a beneficial strategy for many cardiac targeted therapeutics.
Achieving rhythm control in persistent AF is challenging because of the confluence of pathophysiologic factors, including fibrosis, electric remodeling, and autonomic nervous system activation. 36 Amiodarone is effective in treating AF, although its use is limited by off-target organ toxicity. 8, [15] [16] [17] [18] The hydrophobicity of amiodarone delays attainment of therapeutic cardiac levels and contributes to buildup of drug in off-target tissues. For outpatient use, patients are often dosed with a 10-g load and then treated with 200 to 800 mg of drug daily. In the present study, a single 50-mg dose of amiodarone delivered directly to the atrial epicardium sustained therapeutic effects for 4 weeks at 5% of the systemic loading dose (10 g), 25% of the daily dose (200 mg), and 0.3% of the cumulative monthly dose (17 g). 37 The reduced dose lessens the chance for offtarget organ toxicity.
Prior studies have examined the delivery of cardiovascular agents in the pericardial space and may have some advantages over systemic delivery, especially for newer classes of cardiac therapeutics. The space is in direct contact with the cardiac epicardium. The pericardium is also known to act as a barrier slowing systemic distribution of instilled therapeutics in animal trials. [38] [39] [40] Vascular washout of the therapeutic is eliminated because pericardial fluid is only slowly replenished over several hours. 41 There is no risk of vascular occlusion or embolization because the pericardial space is not within the vasculature.
There are several challenges in utilizing the pericardial space. Few physicians have expertise at accessing a pericardial space lacking effusion-a so called dry pericardium. With the advent of epicardial ablations for the treatment of ventricular arrhythmias, as well as the Lariat Device for suturing of the left atrial appendage, invasive cardiologists have gained skill in this technique. In 1 study, there were no reported complications from pericardial access when a micropuncture kit was used. 32 Another limitation of the pericardial space is its propensity for inflammation. Our hydrogel has shown minimal inflammation and no local or systemic toxicity in numerous preclinical settings. 20, 23, 26, 27 Furthermore, utilizing a 1-time intrapericardial steroid dose in conjunction with the anti-inflammatory medication colchicine, we were able to eliminate clinically significant pericardial inflammation. Further studies will be needed to confirm the safety of this therapy during the long term.
In the current study, we do not know the maximum duration of action of amiodarone delivered in this manner. Gel recovered from rats after 28 days still contained amiodarone, and tissue drug levels rose from 7 to 28 days suggesting continual tissue level rise. Longer stud- Pigs were treated with control gel (Cntrl) (n=4) or amiodarone-containing gel (Amio) (n=4). Before gel implantation procedure and 4 wk later, serum albumin, Alk phos, ALT, and bilirubin were measured as markers of liver function and did not differ between groups. Serum creatinine was measured as a marker of kidney function and was higher in Amio-treated animals compared with control before gel placement (2.0±0.3 vs 1.1±0.1 mg/dL; P=0.03) although levels were elevated at baseline before gel delivery and remained stable in the amiodarone group. WBC count and differential were similar between groups. Alk phos indicates alkaline phosphatase; ALT, alanine aminotransferase; Amio, amiodarone-containing gel; Cntrl, control gel; and WBC, white blood cell. *P<0.05.
ies will be needed to understand the duration of drug release and efficacy. For clinical translation, several months of efficacy would be ideal to avoid repeated pericardial procedures. Other formulations, such as liposomes or micro particle encapsulation, may give prolonged duration of release although will likely deliver a smaller amiodarone quantity per volume of gel. Along with the release profile, it is key to determine the inflammatory profile of any material delivered to the pericardial space. Several studies have explored the possibility of antiarrhythmic therapy delivered to the cardiac epicardium. Intrapericardial injection of sotalol, ibutilide, and esmolol showed acute physiological effects, but these drugs have not been tested in chronic studies or extended release gel formulations. 38, 42 Infusion of amiodarone acutely into the pericardial space has been shown to increase cardiac amiodarone levels and have electrophysiological effects. [43] [44] [45] Other groups have developed hydrogels for amiodarone delivery to the heart. These formulations deliver drug over days, not months, for the postoperative cardiac surgery population and require a spray or direct application. [46] [47] [48] Combination patches with steroid formulation have also been studied in rodents. 49 These preparations require direct delivery to the heart and are not amenable to minimally invasive delivery in patients not undergoing open heart surgery.
A challenge for development of amiodarone-delivering gel is the lack of data on the effective cardiac amiodarone levels needed for suppression of atrial and ventricular arrhythmias. With systemic dosing, plasma drug levels do not correlate well with cardiac drug levels. 17 Autopsy studies of patients receiving acute or chronic amiodarone therapy report cardiac drug levels ranging from 1 to 40 μg/g. 17, 35, 50 Drug levels achieved in rat and pig studies are lower than that achieved in these clinical settings, although efficacy was still shown in our animal model. This suggests that lower drug levels many be efficacious in some patients. However, this model may lack pathophysiologic factors that could influence the therapeutic threshold and may underestimate cardiac drug levels needed in sicker patient populations. Further studies will be needed to explore efficacious tissue amiodarone levels.
In conclusion, we show the possibility of utilization of the pericardial space for therapeutic hydrogel delivery. Using our minimally invasive delivery device, an amiodarone-containing hydrogel was placed on the atrial epicardium and showed efficacy for at least 1 month. Complementary small-animal studies showed advantageous tissue amiodarone distribution that could result in reduced toxicity from lower off-target tissue distribution. Further studies on the duration of action and long-term safety are needed before translation of this biomaterial strategy into clinical use. However, this technique could be a more efficient mode of delivery for a variety of new therapeutics, such as stem cells, miRNAs, cytokines, and gene therapy, that would benefit from more direct cardiac localization.
